MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income
Depreciation, amortization and a...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Change in fair value of continge...
Deferred taxes
Gain on conversion of installmen...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
75,029
118,417
54,088
27,771
Depreciation, amortization and accretion
22,582
22,683
22,833
20,408
Impairment of long-lived assets
-
-
0
-
Adjustment to the fair value of asset retirement obligation
0
0
0
0
Amortization of debt-related costs
1,115
1,115
1,114
1,113
Change in fair value of contingent liabilities
31,397
358
-397
-982
Inventory adjustments
454
1,537
-667
1,933
Stock-based compensation
20,007
16,041
17,543
24,501
Gain on disposal of assets
-
-
0
0
Gain on sale of relistor licensed intangible asset
-
-
5,000
-
Unrealized (gain) loss on investment in equity securities
-9,536
14,905
-9,488
1,160
Charges incurred pursuant to acquired in-process research and development
0
0
-5,799
0
Deferred taxes
-13,071
19,327
-1,784
28,956
Long-term indemnification receivable
-
-
0
-
Long-term income tax payable and other long-term liabilities
603
84
3,000
-2,751
Gain on sale of business, net of transaction costs
199
59,328
-
-
Gain on conversion of installment note
2,525
-
-
-
Other
997
2,317
348
-2,259
Accounts receivable
-3,276
2,232
2,067
-12,830
Inventory
-3,301
-2,113
3,041
915
Other current and noncurrent assets
-5,088
244
-938
4,428
Accounts payable
1,390
190
-31,965
20,108
Accrued expenses and other current and noncurrent liabilities
-1,989
23,004
19,850
-26,313
Net cash provided by operating activities
92,203
125,127
90,178
105,294
Capital expenditures
2,335
3,226
8,788
10,622
Acquisition of in-process research and development
0
-
0
0
Proceeds from sale of business, net of transaction costs
0
24,212
-
-
Proceeds from sale of assets
0
5,000
0
0
Acquisition of assets, net
-
-
0
0
Acquisition, net of cash acquired-Lantheus Biosciences Ltd
-312
-
-
-
Acquisition, net of cash acquired-Evergreen Theragnostics
0
-
0
268,933
Acquisition, net of cash acquired-Life Molecular Imaging Ltd
-
-
-2,278
309,011
Deposit for acquisition of a business
-
0
-
-
Purchases of investment in equity securities
0
0
5,000
0
Acquisition of exclusive license option
-
-
0
0
Net cash provided by (used in) investing activities
-2,023
25,986
-11,510
-319,468
Payments of long-term debt and other borrowings
248
216
353
292
Deferred financing costs
-
-
0
-
Proceeds from stock option exercises
6,856
1,697
681
142
Contingent value rights settlement
-
-
0
-
Proceeds from employee stock purchase plan
-1
2,591
1
1,743
Payments for minimum statutory tax withholding related to net share settlement of equity awards
2,102
15,695
1,098
759
Proceeds from issuance of common stock
-
0
-
-
Repurchase of common stock
0
-
100,017
100,000
Net cash used in financing activities
4,505
-11,623
-100,786
-99,166
Effect of exchange rate changes on cash, cash equivalents and restricted cash
36
-22
-760
-218
Net increase (decrease) in cash, cash equivalents and restricted cash
94,721
139,468
-22,878
-313,558
Cash, cash equivalents and restricted cash, beginning of period
500,294
360,826
383,704
914,486
Cash and cash equivalents
593,298
-
-
-
Restricted cash included in other long-term assets
1,717
-
-
-
Cash, cash equivalents and restricted cash, end of period
595,015
500,294
360,826
383,704
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$75,029K
(-4.73%↓ Y/Y)
Depreciation, amortization
and accretion
$22,582K
(70.67%↑ Y/Y)
Proceeds from stock
option exercises
$6,856K
(180.41%↑ Y/Y)
Stock-based compensation
$20,007K
(-10.37%↓ Y/Y)
Unrealized (gain) loss on
investment in equity...
-$9,536K
(-165.44%↓ Y/Y)
Other current and
noncurrent assets
-$5,088K
(-365.55%↓ Y/Y)
Inventory
-$3,301K
(-158.03%↓ Y/Y)
Accounts receivable
-$3,276K
(-243.18%↓ Y/Y)
Accounts payable
$1,390K
(-68.29%↓ Y/Y)
Amortization of debt-related
costs
$1,115K
(0.00%↑ Y/Y)
Long-term income tax
payable and other...
$603K
(193.93%↑ Y/Y)
Inventory adjustments
$454K
(-80.38%↓ Y/Y)
Net cash provided by
operating activities
$92,203K
(5.85%↑ Y/Y)
Net cash used in
financing activities
$4,505K
(104.58%↑ Y/Y)
Canceled cashflow
$50,178K
Effect of exchange rate
changes on cash, cash...
$36K
(-95.65%↓ Y/Y)
Canceled cashflow
$2,351K
Net increase
(decrease) in cash, cash...
$94,721K
(138.99%↑ Y/Y)
Canceled cashflow
$2,023K
Change in fair value of
contingent liabilities
$31,397K
Deferred taxes
-$13,071K
(-88.67%↓ Y/Y)
Gain on conversion of
installment note
$2,525K
Accrued expenses and
other current and...
-$1,989K
(66.55%↑ Y/Y)
Other
$997K
(140.84%↑ Y/Y)
Gain on sale of
business, net of...
$199K
Payments for minimum
statutory tax withholding...
$2,102K
(164.40%↑ Y/Y)
Payments of long-term
debt and other...
$248K
(293.65%↑ Y/Y)
Proceeds from employee
stock purchase plan
-$1K
(-100.05%↓ Y/Y)
Acquisition, net of cash
acquired-Lantheus Biosciences Ltd
-$312K
Net cash provided by
(used in) investing...
-$2,023K
(99.13%↑ Y/Y)
Canceled cashflow
$312K
Capital expenditures
$2,335K
(-70.67%↓ Y/Y)
Buy us a coffee
logo-lantheus-tm-svg
Lantheus Holdings, Inc. (LNTH)
logo-lantheus-tm-svg
Lantheus Holdings, Inc. (LNTH)